27 September 2020: Database Analysis
A Network Pharmacological Approach to Investigate the Mechanism of Action of Active Ingredients of and Their Potential Targets in Treatment of Alzheimer’s Disease
Yajuan Li ABCDEF , Qin Yang BF , Yang Yu AG*DOI: 10.12659/MSM.926295
Med Sci Monit 2020; 26:e926295
Table 2 KEGG signal pathway information.
| Term | Count | Percentage (%) | P value | Genes |
|---|---|---|---|---|
| HIF-1 signaling pathway | 9 | 33.33 | 10 | MAPK1, TF, IL6, HMOX1, BCL2, VEGFA, NOS3, NOS2, INSR |
| TNF signaling pathway | 6 | 22.22 | 3.44×10 | MAPK1, IL6, TNF, CCL2, PTGS2, IL1B |
| Serotonergic synapse | 6 | 22.22 | 4.11×10 | MAPK1, APP, PTGS2, SLC6A4, PTGS1, MAOB |
| NOD-like receptor signaling pathway | 5 | 18.52 | 4.39×10 | MAPK1, IL6, TNF, CCL2, IL1B |
| Prion diseases | 4 | 14.81 | 2.36×10 | MAPK1, IL6, IL1B, SOD1 |
| Rheumatoid arthritis | 5 | 18.52 | 2.58×10 | IL6, TNF, CCL2, VEGFA, IL1B |
| Influenza A | 6 | 22.22 | 3.44×10 | MAPK1, IL6, TNF, CCL2, GSK3B, IL1B |
| Pathways in cancer | 8 | 29.63 | 3.69×10 | MAPK1, IL6, PTGS2, GSK3B, BCL2, VEGFA, PPARG, NOS2 |
| Insulin resistance | 5 | 18.52 | 5.64×10 | IL6, TNF, GSK3B, NOS3, INSR |
| Malaria | 4 | 14.81 | 6.99×10 | IL6, TNF, CCL2, IL1B |
| Sphingolipid signaling pathway | 5 | 18.52 | 8.39×10 | MAPK1, TNF, BCL2, CTSD, NOS3 |
| PI3K-Akt signaling pathway | 7 | 25.93 | 1.2×10 | MAPK1, IL6, GSK3B, BCL2, VEGFA, NOS3, INSR |
| VEGF signaling pathway | 4 | 14.81 | 1.33×10 | MAPK1, PTGS2, VEGFA, NOS3 |
| Non-alcoholic fatty liver disease (NAFLD) | 5 | 18.52 | 1.97×10 | IL6, TNF, GSK3B, IL1B, INSR |
| Alzheimer’s disease | 5 | 18.52 | 2.91×10 | MAPK1, APP, TNF, GSK3B, IL1B |
| Salmonella infection | 4 | 14.81 | 3.22×10 | MAPK1, IL6, IL1B, NOS2 |
| NF-kappa B signaling pathway | 4 | 14.81 | 3.68×10 | TNF, PTGS2, BCL2, IL1B |
| Graft-versus-host disease | 3 | 11.11 | 6.25×10 | IL6, TNF, IL1B |
| Toll-like receptor signaling pathway | 4 | 14.81 | 6.39×10 | MAPK1, IL6, TNF, IL1B |
| Amoebiasis | 4 | 14.81 | 6.39×10 | IL6, TNF, IL1B, NOS2 |